306 related articles for article (PubMed ID: 23523733)
1. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.
Ampe E; Delaere B; Hecq JD; Tulkens PM; Glupczynski Y
Int J Antimicrob Agents; 2013 May; 41(5):439-46. PubMed ID: 23523733
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
3. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
[TBL] [Abstract][Full Text] [Related]
4. [Level of evidence for therapeutic drug monitoring of vancomycin].
Jelassi ML; Benlmouden A; Lefeuvre S; Mainardi JL; Billaud EM;
Therapie; 2011; 66(1):29-37. PubMed ID: 21466775
[TBL] [Abstract][Full Text] [Related]
5. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin: we can't get there from here.
Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion.
De Waele JJ; Danneels I; Depuydt P; Decruyenaere J; Bourgeois M; Hoste E
Int J Antimicrob Agents; 2013 May; 41(5):434-8. PubMed ID: 23410793
[TBL] [Abstract][Full Text] [Related]
8. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.
Hutschala D; Kinstner C; Skhirdladze K; Thalhammer F; Müller M; Tschernko E
Anesthesiology; 2009 Aug; 111(2):356-65. PubMed ID: 19602966
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.
Silva DC; Seixas GT; Araujo OR; Arduini RG; Carlesse FA; Petrilli AS
Braz J Infect Dis; 2012; 16(4):361-5. PubMed ID: 22846125
[TBL] [Abstract][Full Text] [Related]
10. Continuous intravenous administration of vancomycin in medical intensive care unit patients.
Saugel B; Nowack MC; Hapfelmeier A; Umgelter A; Schultheiss C; Thies P; Phillip V; Eyer F; Schmid RM; Huber W
J Crit Care; 2013 Feb; 28(1):9-13. PubMed ID: 22459156
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia.
Hochart C; Berthon C; Corm S; Gay J; Cliquennois M; Tricot S; Alfandari S
Med Mal Infect; 2011 Dec; 41(12):652-6. PubMed ID: 22056376
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.
Ingram PR; Lye DC; Tambyah PA; Goh WP; Tam VH; Fisher DA
J Antimicrob Chemother; 2008 Jul; 62(1):168-71. PubMed ID: 18334494
[TBL] [Abstract][Full Text] [Related]
13. A higher dose of vancomycin in continuous infusion is needed in critically ill patients.
Jeurissen A; Sluyts I; Rutsaert R
Int J Antimicrob Agents; 2011 Jan; 37(1):75-7. PubMed ID: 21074374
[TBL] [Abstract][Full Text] [Related]
14. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
James JK; Palmer SM; Levine DP; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):696-700. PubMed ID: 8851595
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
16. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug.
Brown DL; Lalla CD; Masselink AJ
Ther Drug Monit; 2013 Aug; 35(4):443-9. PubMed ID: 23851909
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacodynamic profile of commonly used intravenous vancomycin dosing schemes in patients on automated peritoneal dialysis.
Cardone KE; Chen WZ; Grabe DW; Batzold A; Manley HJ; Lodise TP
J Antimicrob Chemother; 2014 Jul; 69(7):1873-6. PubMed ID: 24722842
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin Therapeutic Targets and Nephrotoxicity in Critically Ill Children With Cancer.
Seixas GT; Araujo OR; Silva DC; Arduini RG; Petrilli AS
J Pediatr Hematol Oncol; 2016 Mar; 38(2):e56-62. PubMed ID: 26558810
[TBL] [Abstract][Full Text] [Related]
19. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Lubenko IY; Strukova EV; Smirnova MV; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
[TBL] [Abstract][Full Text] [Related]
20. Switching From Intermittent to Continuous Infusion of Vancomycin in Critically Ill Patients: Toward a More Robust Exposure.
van Maarseveen EM; Gipmans S; Vasbinder E; Petjak M; van Zanten AR
Ther Drug Monit; 2016 Jun; 38(3):398-401. PubMed ID: 26926670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
